Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Validation of a Novel Rac1 Inhibitor As Potent Secdrug Against Activating Ras Mutant and Drug-Resistant Multiple Myeloma

Salsabil Ahmed, Suman Mazumder, Lisa Wiesen, Neeraj Sharma, Ujjal Kumar Mukherjee, Shaji K Kumar, Linda B. Baughn, Brian G. Van Ness, Amit Kumar Mitra

Blood (2022) 140 (Supplement 1): 4249–4250.

https://doi.org/10.1182/blood-2022-164501

Published: 2022

Journal Articles

The Anti-Leprosy Drug Clofazimine Synergizes with BTK Inhibitors and Proteasome Inhibitors in Drug-Resistant Mantle Cell Lymphoma

Sayak Chakravarti, Harish Kumar, Suman Mazumder, Sabyasachi Sanyal, Brian G. Van Ness, Amit Kumar Mitra

Blood (2021) 138 (Supplement 1): 1190.

https://doi.org/10.1182/blood-2021-154377

Published: 2021

Journal Articles

Establishing a Novel Pipeline That Combines in-Silico Prediction with in-Vitro and Ex-Vivo V alidation to Discover Secondary Drug Combinations Against Relapsed and/or Refractory Multiple Myeloma

Sayak Chakravarti, Suman Mazumder, Harish Kumar, Neeraj Sharma, Ujjal Kumar Mukherjee, Shaji Kumar, Linda B Baughn, Brian G. Van Ness, Amit Kumar Mitra

Blood (2021) 138 (Supplement 1): 1615.

https://doi.org/10.1182/blood-2021-154521

Published: 2021

Journal Articles

Phenotypic and Functional Characterization of Multiple Myeloma By Single Cell Mass Cytometry (CyTOF)

Linda B Baughn, PhD, Erik Jessen, PhD, Matthew Smith, Neeraj Sharma, PhD, Joselle Cook, MBBS, Surendra Dasari, PhD, Kathryn E. Pearce, MS, Nathalie Meurice, PhD, Michael A. Linden, MDPhD, A. Keith Stewart, MB, ChB, P. Leif Bergsagel, MD, Brian G. Van Ness, PhD, Shaji K. Kumar, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-141639

Published: 2020

Journal Articles

Repurposing Clofazimine As a Novel Drug for the Treatment of PI-Resistant Stem Cell-like Subclones in Myeloma

Harish Kumar, PhD, Ujjal Kumar Mukherjee, PhD, Suman Mazumder, PhD, Sabyasachi Sanyal, PhD, Brian G. Van Ness, PhD, Amit Kumar Mitra, PhD MSc, BSc

Blood (2019) 134 (Supplement_1): 4418.

https://doi.org/10.1182/blood-2019-131596

Published: 2019

Journal Articles

Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and -Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology

Ian Ferguson, BA, Yu-Hsiu T. Lin, BA, Sami Tuomivaara, PhD, Jeffrey L. Wolf, MD, Thomas G. Martin, III, MD, Sandy W. Wong, MD, Nina D. Shah, MD, Christoph Driessen, MD, Brian G. Van Ness, PhD, Arun P. Wiita, MD PhD

Blood (2019) 134 (Supplement_1): 1803.

https://doi.org/10.1182/blood-2019-131681

Published: 2019

Journal Articles

Secdrug: A Computational Method for Discovering Novel Secondary Drug Combinations Using Large-Scale Pharmacogenomics Databases

Li Chen, PhD, Ujjal Kumar Mukherjee, PhD, Emily Rankine, Brian G. Van Ness, PhD, Amit Kumar Mitra, PhD

Blood (2018) 132 (Supplement 1): 4473.

https://doi.org/10.1182/blood-2018-99-117653

Published: 2018

Journal Articles

Gene Expression Profiling of Kinetic Response to Proteasome Inhibitors in Innate and Acquired Resistant Multiple Myeloma

Amit Kumar Mitra, PhD, Vijay G. Ramakrishnan, PhD, Shaji K Kumar, MD, S. Vincent Rajkumar, MD, Brian G. Van Ness, PhD

Blood (2017) 130 (Supplement 1): 4405.

https://doi.org/10.1182/blood.V130.Suppl_1.4405.4405

Published: 2017

Journal Articles

Scattome: A Single-Cell Analysis of Targeted Transcriptome Program to Predict Drug Sensitivity of Single Cells within Human Myeloma Tumors

Amit Kumar Mitra, PhD, Ujjal Mukherjee, PhD, Taylor Harding, Holly Stessman, PhD, Ying Li, Jen Jin, Shaji K Kumar, MD, S. Vincent Rajkumar, Brian G Van Ness, PhD

Blood (2015) 126 (23): 4249.

https://doi.org/10.1182/blood.V126.23.4249.4249

Published: 2015

Journal Articles

Creation of a Gene Expression Signature-Based Prediction Model Specific to Proteasome Inhibitor Response in Multiple Myeloma

Amit Kumar Mitra, PhD, Ujjal Mukherjee, PhD, Taylor Harding, Snigdhansu Chatterjee, PhD, Brian G Van Ness, PhD

Blood (2015) 126 (23): 3053.

https://doi.org/10.1182/blood.V126.23.3053.3053

Published: 2015

Journal Articles

MLN9708 Elicits Pharmacodynamic Response in the Bone Marrow Compartment and Has Strong Antitumor Activity in a Preclinical Intraosseous Model of Plasma Cell Malignancy.

Edmund Lee, Bret Bannerman, Michael Fitzgerald, Jennifer Terkelsen, Daniel Bradley, Zhi Li, Ping Li, Siegfried Janz, Brian G Van Ness, Mark Manfredi, Erik Kupperman

Blood (2009) 114 (22): 1834.

https://doi.org/10.1182/blood.V114.22.1834.1834

Published: 2009

Journal Articles

Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma.

Sophie L Corthals, David C Johnson, Yvonne de Knegt, Hartmut Goldschmidt, Henk Lokhorst, Stéphane Minvielle, Florence Magrangeas, Jean-Luc Harousseau, Brian G M Durie, Brian G Van Ness, Gareth J Morgan, Pieter Sonneveld, Hervé Avet Loiseau

Blood (2009) 114 (22): 1794.

https://doi.org/10.1182/blood.V114.22.1794.1794

Published: 2009

Journal Articles

Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients.

Rowan Kuiper, Sophie L Corthals, Payman Hanifi-Moghaddam, Yvonne de Knegt, Henk Lokhorst, Hartmut Goldschmidt, Brian G M Durie, Brian G Van Ness, Gareth J Morgan, Mark van Duin, Herve Avet-Loiseau, Pieter Sonneveld

Blood (2009) 114 (22): 1800.

https://doi.org/10.1182/blood.V114.22.1800.1800

Published: 2009

Journal Articles

Evaluating the Antitumor Activity of MLN9708 in a Disseminated Mouse Model of Double Transgenic iMyc Ca /Bcl-X L Plasma Cell Malignancy.

Michael Fitzgerald, Yueying Cao, Bret Bannerman, Zhi Li, Olga Tayber, Ping Li, Jennifer Terkelsen, Daniel Bradley, Jonathan Frazer, Lee Silverman, PhD, Siegfried Janz, Brian G Van Ness, Erik Kupperman, Mark Manfredi, Edmund Lee

Blood (2009) 114 (22): 3835.

https://doi.org/10.1182/blood.V114.22.3835.3835

Published: 2009

Journal Articles

Combined Measurement of Plasma Cell Proliferation and Apoptosis in Multiple Myeloma.

Jiri Minarik, Vlastimil Scudla, Marta Ordeltova, Tomas Pika, Jaroslav Bacovsky, Michael Steinbach, Vipin Kumar, Brian G Van Ness

Blood (2009) 114 (22): 4884.

https://doi.org/10.1182/blood.V114.22.4884.4884

Published: 2009

Journal Articles

Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations.

David C Johnson, BSc, Walter M Gregory, PhD, Nicholas J Dickens, DPhil, Brian A Walker, PhD, Alex J Szubert, MSc, Faith E Davies, MD, Brian G M Durie, MD, Brian G Van Ness, PhD, Gareth J Morgan, MD, PhD

Blood (2009) 114 (22): 426.

https://doi.org/10.1182/blood.V114.22.426.426

Published: 2009

Journal Articles

The Novel Proteasome Inhibitor MLN9708 Demonstrates Efficacy in a Genetically-Engineered Mouse Model of DeNovo Plasma Cell Malignancy.

Siegfried Janz, Brian G Van Ness, Vishala Neppalli, Ray Liu, Michael D Pickard, Jennifer Terkelsen, Daniel Bradley, Ling Hu, Erik Kupperman, Mark Manfredi, Edmund Lee

Blood (2009) 114 (22): 3849.

https://doi.org/10.1182/blood.V114.22.3849.3849

Published: 2009

Journal Articles

Transgenic Mouse Modeling of Therapeutic Responses in Myeloma

Brian G. Van Ness, PhD, Christine Ramos, Mary Gosse

Blood (2008) 112 (11): 2747.

https://doi.org/10.1182/blood.V112.11.2747.2747

Published: 2008

Journal Articles

Analytical Approaches for the BOAC SNP Panel Association with Progression Free Survival in Myeloma

Brian G. Van Ness, PhD, Christine Ramos, Vipin Kumar, Michael Steinbach, Brian GM Durie, MD, John Crowley, PhD, Bart Barlogie, Antje Hoering, Jeff Haessler, David C Johnson, Gareth J Morgan, MD, PhD

Blood (2008) 112 (11): 2715.

https://doi.org/10.1182/blood.V112.11.2715.2715

Published: 2008

Journal Articles

Genetic Variation in ADME Genes Is Associated with Thalidomide Related Peripheral Neuropathy in Multiple Myeloma Patients.

David C Johnson, Christine Ramos, Alex J. Szubert, Walter M Gregory, J. Anthony Child, Faith E Davies, MD, Brian GM Durie, MD, Brian G. Van Ness, PhD, Gareth J Morgan, MD, PhD

Blood (2008) 112 (11): 1675.

https://doi.org/10.1182/blood.V112.11.1675.1675

Published: 2008

NARROW

Validation of a Novel Rac1 Inhibitor As Potent Secdrug Against Activating Ras Mutant and Drug-Resistant Multiple Myeloma

The Anti-Leprosy Drug Clofazimine Synergizes with BTK Inhibitors and Proteasome Inhibitors in Drug-Resistant Mantle Cell Lymphoma

Establishing a Novel Pipeline That Combines in-Silico Prediction with in-Vitro and Ex-Vivo V alidation to Discover Secondary Drug Combinations Against Relapsed and/or Refractory Multiple Myeloma

Phenotypic and Functional Characterization of Multiple Myeloma By Single Cell Mass Cytometry (CyTOF)

Repurposing Clofazimine As a Novel Drug for the Treatment of PI-Resistant Stem Cell-like Subclones in Myeloma

Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and -Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology

Secdrug: A Computational Method for Discovering Novel Secondary Drug Combinations Using Large-Scale Pharmacogenomics Databases

Gene Expression Profiling of Kinetic Response to Proteasome Inhibitors in Innate and Acquired Resistant Multiple Myeloma

Scattome: A Single-Cell Analysis of Targeted Transcriptome Program to Predict Drug Sensitivity of Single Cells within Human Myeloma Tumors

Creation of a Gene Expression Signature-Based Prediction Model Specific to Proteasome Inhibitor Response in Multiple Myeloma

MLN9708 Elicits Pharmacodynamic Response in the Bone Marrow Compartment and Has Strong Antitumor Activity in a Preclinical Intraosseous Model of Plasma Cell Malignancy.

Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma.

Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients.

Evaluating the Antitumor Activity of MLN9708 in a Disseminated Mouse Model of Double Transgenic iMyc Ca /Bcl-X L Plasma Cell Malignancy.

Combined Measurement of Plasma Cell Proliferation and Apoptosis in Multiple Myeloma.

Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations.

The Novel Proteasome Inhibitor MLN9708 Demonstrates Efficacy in a Genetically-Engineered Mouse Model of DeNovo Plasma Cell Malignancy.

Transgenic Mouse Modeling of Therapeutic Responses in Myeloma

Analytical Approaches for the BOAC SNP Panel Association with Progression Free Survival in Myeloma

Genetic Variation in ADME Genes Is Associated with Thalidomide Related Peripheral Neuropathy in Multiple Myeloma Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only